ST-162

• Description :

  ST-162 is a MAPK/PI3K dual antagonist. ST-162 exhibits antitumor activity and can increase the efficacy of immune checkpoint blockers. ST-162 can be used for the research of cancer, such as melanoma[1].

• UNSPSC :

  12352005

• Target :

  P38 MAPK; PI3K

• Related Pathways :

  MAPK/ERK Pathway; PI3K/Akt/mTOR

• Field of Research :

  Cancer

• Smiles :

  O=C(NOCCOCCOCCOCCN1CCN(C2=NC(N3C4=CC=CC=C4N=C3C(F)F)=NC(N5CCOCC5)=N2)CC1)C6=CC=C(F)C(F)=C6NC7=CC=C(I)C=C7F

• Molecular Formula :

  C40H44F5IN10O6

• Molecular Weight :

  982.74

• References & Citations :

  [1]Galbán S, et al. A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. Mol Cancer Ther. 2017 Nov;16 (11) :2340-2350.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1883817-83-1]